| Literature DB >> 36068861 |
Anacleto Silva de Souza1, Vitor Martins de Freitas Amorim1, Gabriela D A Guardia2, Felipe R C Dos Santos2,3, Filipe F Dos Santos2,4, Robson Francisco de Souza1, Guilherme de Araujo Juvenal4, Yihua Huang5, Pingju Ge5, Yinan Jiang5, Coco Li5, Prajwal Paudel5, Henning Ulrich4, Pedro A F Galante2, Cristiane Rodrigues Guzzo1.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is evolving with mutations in the spike protein, especially in the receptor-binding domain (RBD). The failure of public health measures in some countries to contain the spread of the disease has given rise to novel viral variants with increased transmissibility. However, key questions about how quickly the variants can spread remain unclear. Herein, we performed a structural investigation using molecular dynamics simulations and determined dissociation constant (K D) values using surface plasmon resonance assays of three fast-spreading SARS-CoV-2 variants, alpha, beta, and gamma, as well as genetic factors in host cells that may be related to the viral infection. Our results suggest that the SARS-CoV-2 variants facilitate their entry into the host cell by moderately increased binding affinities to the human ACE2 receptor, different torsions in hACE2 mediated by RBD variants, and an increased spike exposure time to proteolytic enzymes. We also found that other host cell aspects, such as gene and isoform expression of key genes for the infection (ACE2, FURIN, and TMPRSS2), may have few contributions to the SARS-CoV-2 variant infectivity. In summary, we concluded that a combination of viral and host cell factors allows SARS-CoV-2 variants to increase their abilities to spread faster than the wild type.Entities:
Year: 2022 PMID: 36068861 PMCID: PMC9437663 DOI: 10.1021/acsomega.1c07240
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Illustration of mutations in the S protein gene in different variants of SARS-CoV-2. (a) The RBD (residues 333–526) and the furin cleavage site (S1/S2) (residues 682–685) are colored in light green and salmon boxes, respectively. All mutations are represented by black lines and typed in red. Mutations that are found to be mutated for different residues are colored in blue and green. The green line shows different mutations in the same location. All SARS-CoV-2 variants shown in the figure have D614G, an advantage mutation for SARS-CoV-2. D614G has enhanced spike stability and transmission but does not significantly increase the binding affinity for hACE2 at 37 °C.[37−39] VOC: variant of concern. (b) Cartoon representation of the RBD/hACE2 interface complex (PDB ID: 6M0J4). RDB presents two different regions, E1 (residues 417, 455–456, and 470–490) and E2 (444–454 and 493–505). The residues mutated in RBD of SARS-CoV-2 variants are K417, E484 (does not make part of the interface), and N501. RBDB.1.1.7 (alpha variant) has the mutation N501Y; RBDB.1.351 (beta variant) has K417N, E484K, and N501Y mutations; and RBDP.1 (gamma variant) has K417T, E484K, and N501Y mutations.
Figure 2Structural aspects obtained by molecular dynamics simulations of different SARS-CoV-2 RBD variants while interacting with hACE2. Backbone RMSD probability distributions are shown for (a) hACE2 and (b) RBD. Backbone RMSF are shown for (c) hACE2 and (d) RBD. The Panels (e–g) show different conformational changes of each RBDvariant/hACE2 complex in relation to the RBDWT/hACE2 complex. Note that the main structural differences are localized in the loop 474–488 caused by the N501Y mutation in RBDB.1.1.7 (e) that is partially recovered in RBDP.1 (f) and RBDB.1.351 (g). Residues 469−490 are colored in red in the RBDWT/hACE2 complex. The structure models of RBDWT/hACE2, RBDB.1.1.7/hACE2, RBDP.1/hACE2 and RBDB.1.351/hACE2 were taken from a snapshot at 40 ns, 19 ns, 61 ns, and 42 ns, respectively, from each MD simulation trajectory. We observed in another independent calculation simulated for 300 ns for hACE2 in complex with RBDWT, RBDB.1.1.7, and RBDP.1, showing the same structural behavior (Figures S15–S17).
Figure 3Correlation matrix obtained by MD trajectories of RBD and its variants interacting with hACE2. Painels (a–d) show heat maps representing the correlation matrix of the interface residues. Anti-correlated and correlated pairs are colored in red and blue, respectively. Note that correlated and anti-correlated pairs are affected in E1 and E2 regions of RBD variants, mostly in RBDB.1.1.7. Heat maps of RBDB.1.351 and RBDP.1 have similar patterns to that of RBDWT.
Figure 4MD trajectories obtained by principal component analysis. Principal component analysis using MD trajectories of hACE2 in complex with (a) RBDWT, (b) RBDB.1.1.7, (c) RBDB.1.351, and (d) RBDP.1. Each panel has 100 snapshots corresponding to MD trajectories obtained from the first component. The movements of the RBD variants induce different torsions in the hACE2 (Supporting Information, Movies S1 and S2).
Kinetic Parameters Obtained from SPR Assaysa
| variant | |||
|---|---|---|---|
| RBDWT | 6.6 ± 2.0 | 93.4 ± 1.7 | 15.0 ± 4.1 |
| RBDB.1.1.7 (alpha) | 9.0 ± 3.0 | 15.5 ± 0.1 | 1.8 ± 0.5 |
| RBDB.1.351 (beta) | 9.0 ± 2.7 | 40.9 ± 1.3 | 4.8 ± 1.4 |
| RBDP.1 (gamma) | 9.0 ± 3.4 | 27.8 ± 0.9 | 3.3 ± 1.0 |
| spike trimerWT | 0.7 ± 0.2 | 4.8 ± 0.8 | 6.7 ± 1.3 |
| spike trimerB.1.1.7 (alpha) | 0.8 ± 0.2 | 1.5 ± 0.1 | 1.9 ± 0.2 |
| spike trimerB.1.351 (beta) | 1.6 ± 0.9 | 2.1 ± 0.7 | 1.4 ± 0.3 |
| spike trimerP.1 (gamma) | 1.2 ± 0.5 | 2.4 ± 0.5 | 2.1 ± 0.3 |
Equilibrium dissociation constants (KD’s) calculated for RBD and its variants in complex with the dimeric hACE2 protein. Experimental KD values were also measured using a trimeric spike protein and its variants for interacting with the dimeric form of hACE2 (residues 18–740) fused with a human IgG1 Fc tag at the C-terminus. The mutations in each spike constructions are shown in parentheses: RBDB.1.1.7 (N501Y); RBDB.1.351 (K417N, E484K, and N501Y); RBDP.1 (K417T, E484K, and N501Y); spike trimerB.1.1.7 (H69-V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H); spike trimerB.1.351 (L18F, D80A, D215G, L242-A243-L244del, R246I, K417N, E484K, N501Y, D614G, and A701V); spike trimerP.1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F). In spike trimer constructions, the proline substitutions (F817P, A892P, A899P, A942P, K986P, and V987P) were introduced to stabilize the trimeric prefusion state of the SARS-CoV-2 spike protein, and alanine substitutions (R683A and R685A) were introduced to abolish the furin cleavage site. More details are shown in Table S7. The SPR assays were performed in three biological replicates.
KD = kd/ka.
Figure 5ACE2 is expressed in critical tissues for the disease, its splicing isoforms are less expressed than its full-length sequence, and there is no significant expression difference between gender or age for this gene. (a) ACE2 gene expression profile in 32 human healthy tissues. (b) Expression profile of ACE2 splicing isoforms. (c) ACE2 expression profile segmented by age (young < 40 years of age; old > 60 years of age) and gender. (d) Expression correlation (Rho = Spearman’s correlation coefficient) between ACE2 and FURIN or ACE2 and TMPRSS2.